Yukihiro Shibata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yukihiro Shibata has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Akihiro Hisaka
Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences Chiba University Chiba Japan
3 shared publications - Hiromi Sato
Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences Chiba University Chiba Japan
3 shared publications - Yuta Tamemoto
Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-city 260-8675, Chiba, Japan
3 shared publications - Aoi Yoshitomo
Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8675, Japan
2 shared publications Hirokazu Akada
Department of Psychiatry, Japanese Red Cross Narita Hospital, Narita, Japan
2 shared publicationsKaori Koike
Department of Psychiatry, Japanese Red Cross Narita Hospital, Narita, Japan
2 shared publications
Latest Publications
- 25 August 2026
- Published by Springer Nature in Sleep and Biological Rhythms
- Vol. 24 (4) , 545-554
Association of delayed hospital lights-off time with hypnotic medication use and sleep outcomes in Japan
- 25 August 2026
- Published by Springer Nature in Sleep and Biological Rhythms
- Vol. 24 (4) , 545-554
Association of delayed hospital lights-off time with hypnotic medication use and sleep outcomes in Japan
- Open Access
- 8 September 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (3) , e70054
Effect of Lemborexant‐Based Sleep Medication Formulary on Benzodiazepine Reduction and Clinical Outcomes: A Single‐Center Retrospective Study
Benzodiazepine and non‐benzodiazepine hypnotics (Z‐drugs) are known risk factors for adverse events, including delirium and falls. Although formularies are intended to promote appropriate prescribing, few comprehensive studies have assessed their clinical impact in the context of sleep medications. This study aimed to evaluate changes in hypnotic prescribing patterns and associated clinical outcomes following the implementation of a sleep medication formulary. A psychiatric liaison team developed and implemented a formulary in April 2024, recommending lemborexant as the first‐line treatment and eszopiclone as the second‐line option. This single‐center, retrospective study compared patients admitted and discharged during the 12 months before (April 2023 to March 2024; n = 12 633) and after (April 2024 to March 2025; n = 12 931) implementation. Outcome measures included monthly prescription volumes, diazepam equivalents, use in clinical pathways and prescription sets, delirium incidence, nighttime falls, and length of hospital stay. Statistical analyses were performed using the Mann–Whitney U ‐test and Fisher's exact test. Following implementation, prescription volumes of lemborexant and eszopiclone increased significantly, whereas diazepam equivalents decreased from 10 682 mg to 4117 mg. All 104 clinical pathways and prescription sets previously using benzodiazepine hypnotics or Z‐drugs were converted to lemborexant. Monthly delirium cases declined from 12.5 to 8.0, and the proportion of nighttime falls among patients receiving benzodiazepine hypnotics or Z‐drugs decreased from 24.0% to 11.5%. The median hospital stay also decreased from 8 to 7 days. These findings suggest that formulary implementation effectively optimized hypnotic prescribing and contributed to improved clinical outcomes and patient safety in an acute care setting.
- 8 September 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (3) , e70054
Open AccessEffect of Lemborexant‐Based Sleep Medication Formulary on Benzodiazepine Reduction and Clinical Outcomes: A Single‐Center Retrospective Study
Benzodiazepine and non‐benzodiazepine hypnotics (Z‐drugs) are known risk factors for adverse events, including delirium and falls. Although formularies are intended to promote appropriate prescribing, few comprehensive studies have assessed their clinical impact in the context of sleep medications. This study aimed to evaluate changes in hypnotic prescribing patterns and associated clinical outcomes following the implementation of a sleep medication formulary. A psychiatric liaison team developed and implemented a formulary in April 2024, recommending lemborexant as the first‐line treatment and eszopiclone as the second‐line option. This single‐center, retrospective study compared patients admitted and discharged during the 12 months before (April 2023 to March 2024; n = 12 633) and after (April 2024 to March 2025; n = 12 931) implementation. Outcome measures included monthly prescription volumes, diazepam equivalents, use in clinical pathways and prescription sets, delirium incidence, nighttime falls, and length of hospital stay. Statistical analyses were performed using the Mann–Whitney U ‐test and Fisher's exact test. Following implementation, prescription volumes of lemborexant and eszopiclone increased significantly, whereas diazepam equivalents decreased from 10 682 mg to 4117 mg. All 104 clinical pathways and prescription sets previously using benzodiazepine hypnotics or Z‐drugs were converted to lemborexant. Monthly delirium cases declined from 12.5 to 8.0, and the proportion of nighttime falls among patients receiving benzodiazepine hypnotics or Z‐drugs decreased from 24.0% to 11.5%. The median hospital stay also decreased from 8 to 7 days. These findings suggest that formulary implementation effectively optimized hypnotic prescribing and contributed to improved clinical outcomes and patient safety in an acute care setting.
- 14 March 2025
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 62, 101480
Buffer compositions strongly impact the in vitro assessment of CYP fraction metabolized using human liver microsomes or expressed isoenzymes
- 14 March 2025
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 62, 101480
Buffer compositions strongly impact the in vitro assessment of CYP fraction metabolized using human liver microsomes or expressed isoenzymes
- 19 February 2023
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 53, 100498
Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants
- 19 February 2023
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 53, 100498
Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants
- 1 August 2021
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 39, 100396
Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6
- 1 August 2021
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 39, 100396
Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6